AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that two abstracts on its research platform NeuroRestore have been accepted for poster presentation at the 2nd Swedish Meeting for Alzheimer Research, which this year will be held in Stockholm on April 21.
The abstracts, titled Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors, and A positive modulator of neurotrophin receptors improves cognition and mitochondrial function, will be presented at the 2nd Swedish Meeting for Alzheimer Research by the main authors Kristin Önnestam and Dr. Cristina Parrado-Fernández. Other authors include Dr. Johan Sandin, CSO, Dr. Pontus Forsell, Head of Discovery and Dr. Märta Segerdahl, CMO at AlzeCure.
The results include data from the clinical phase I SAD study with ACD856, where the drug candidate was administered orally to healthy individuals in incremental doses. The substance displayed very good pharmacokinetic properties and had a good safety and tolerability profile in humans. ACD856, which is a positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, has in previous preclinical studies been shown to improve cognition and memory and is developed primarily for the treatment of Alzheimer's disease.
Moreover, new important preclinical data are presented that show a dose-dependent positive effect of both neurotrophins and the NeuroRestore substance AC-0027136 on mitochondrial function, which may be of key importance in neurodegenerative diseases, that are characterized by impaired mitochondrial function. AC-0027136 was also able to significantly improve learning and long-term memory of aged animals.
“These results further strengthen our confidence in the target mechanism and demonstrate the breadth of effects within the NeuroRestore platform. We look forward to the continued clinical development of ACD856 as a new treatment for Alzheimer's disease, an indication with great medical needs and will also continue to explore other opportinities", says Martin Jönsson, CEO of AlzeCure Pharma AB.
The abstract and the poster will be available on AlzeCure’s website after the presentation (https://www.alzecurepharma.se/en/publications).
